CVS Health today announced that it had launched Cordavis, a wholly-owned subsidiary that will work directly with manufacturers to commercialize and/or co-produce private brand biosimilar products (an FDA-approved biologic medication that is highly similar to and has no clinically meaningful differences from a biologic medicine already approved by the FDA) for the U.S. pharmaceutical